High Level Pharmaceutical Forum. Core principles on relative effectiveness. Brussels: European Commission: Healthcare Industries Working Group on Relative Effectiveness; 2008:10.
Eichler, H-G, Abadie, E, Breckenridge, A, et al.
Bridging the efficacy-effectiveness gap: A regulator's perspective on addressing variability of drug response. Nat Rev Drug Discov. 2011;10:495–506.
Towse, A, Jonsson, B, McGrath, C, et al. Understanding variations in relative effectiveness: A health production approach. Int J Technol Assess Health Care. (submitted).
Jönsson, B. Relative effectiveness and the European pharmaceutical market. Eur J Cancer. 2011;12:97–102.
Mestre-Ferrandiz, J, Puig-Peiró, R, Towse, A. Researching the relative efficacy and relative effectiveness of medicines across Europe. OHE Consulting Report. London: Office of Health Economics; 2010.
Autier, P, Boniol, M, La Vecchia, C, et al.
Disparities in breast cancer mortality trends between 30 European countries: Retrospective trend analysis of WHO mortality database. BMJ. 2010;341:c3620.
Berrino, F, De Angelis, R, Sant, M, et al.
Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995–99: Results of the EUROCARE-4 study. Lancet Oncol. 2007;8:773–783.
Botha, JL, Bray, F, Sankila, R, Parkin, DM. Breast cancer incidence and mortality trends in 16 European countries. Eur J Cancer. 2003;39:1718–1729.
Bray, F, Sankila, R, Ferlay, J, Parkin, DM. Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer. 2002;38:99–166.
Coleman, MP, Forman, D, Bryant, H, et al.
Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the International Cancer Benchmarking Partnership): An analysis of population-based cancer registry data. Lancet. 2011;377:127–138.
Karim-Kos, HE, de Vries, E, Soerjomataram, I, et al.
Recent trends of cancer in Europe: A combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer. 2008;44:1345–1389.
Sant, M, Aareleid, T, Berrino, F, et al.
EUROCARE-3: Survival of cancer patients diagnosed 1990–94–Results and commentary. Ann Oncol. 2003;14
Sant, M, Allemani, C, Capocaccia, R, et al.
Stage at diagnosis is a key explanation of differences in breast cancer survival across Europe. Int J Cancer. 2003;106:416–422.
Sant, M, Allemani, C, Santaquilani, M, et al.
EUROCARE-4. Survival of cancer patients diagnosed in 1995–1999. Results and commentary. Eur J Cancer. 2009;45:931–991.
Sant, M, Capocaccia, R, Coleman, MP, et al.
Cancer survival increases in Europe, but international differences remain wide. Eur J Cancer. 2001;37:1659–1667.
Sant, M, EUROCARE Working Group. Overview of EUROCARE-2 results on survival of cancer patients diagnosed 1985–1989. In: Berrino, F, Capocaccia, R, Estève, J, et al., eds. Survival of cancer patients in Europe: The EUROCARE-2 Study, vol. 151. Geneva: WHO Press; 1999.
Sant, M, Francisci, S, Capocaccia, R, et al.
Time trends of breast cancer survival in Europe in relation to incidence and mortality. Int J Cancer. 2006;119:2417–2422.
Woods, LM, Coleman, MP., Lawrence, G., et al.
Evidence against the proposition that “UK cancer survival statistics are misleading”: Simulation study with National Cancer Registry data. BMJ. 2011;342:2011.
Davies, EA, Linklater, KM, Coupland, VH, et al.
Investigation of low 5-year relative survival for breast cancer in a London cancer network. Br J Cancer. 2010;103:1076–1080.
Jones, AP, Haynes, R, Sauerzapf, V, et al.
Travel times to health care and survival from cancers in Northern England. Eur J Cancer. 2008;44:269–274.
Kaffashian, F, Godward, S, Davies, T, et al.
Socioeconomic effects on breast cancer survival: Proportion attributable to stage and morphology. Br J Cancer. 2003;89:1693–1696.
Lim, H-S, Roychoudhuri, R, Peto, J, et al.
Cancer survival is dependent on season of diagnosis and sunlight exposure. Int J Cancer. 2006;119:1530–1536.
Morris, E, Haward, RA, Gilthorpe, MS, Craigs, C, Forman, D. The impact of the Calman-Hine report on the processes and outcomes of care for Yorkshire's breast cancer patients. Ann Oncol. 2008;19:284–291.
Pisani, P, Forman, D. Declining mortality from breast cancer in Yorkshire, 1983–1998: Extent and causes. Br J Cancer. 2004;90:652–656.
Rachet, B, Maringe, C, Nur, U, et al.
Population-based cancer survival trends in England and Wales up to 2007: An assessment of the NHS cancer plan for England. Lancet Oncol. 2009;10:351–369.
Robinson, D, Bell, J, Moller, H, Salman, A. A 13-year follow-up of patients with breast cancer presenting to a District General Hospital breast unit in southeast England. Breast. 2006;15:173–180.
Sloggett, A, Young, H, Grundy, E. The association of cancer survival with four socioeconomic indicators: A longitudinal study of the older population of England and Wales 1981–2000. BMC Cancer. 2007;7:20.
Cabanes, A, Vidal, E, Perez-Gomez, B, et al.
Age-specific breast, uterine and ovarian cancer mortality trends in Spain: Changes from 1980 to 2006. Cancer Epidemiol. 2009;33:169–175.
Fernandez, E, Gonzalez, JR, Borras, JM, et al.
Recent decline in cancer mortality in Catalonia (Spain). A joinpoint regression analysis. Eur J Cancer. 2001;37:2222–2228.
Larrañaga, N, Sarasqueta, C, Martinez-Camblor, P, et al.
Female breast cancer in Gipuzkoa: Prognostic factors and survival. Clin Transl Oncol. 2009;11:96–102.
Vilaprinyo, E, Rue, M, Marcos-Gragera, R, Martinez-Alonso, M. Estimation of age- and stage-specific Catalan breast cancer survival functions using US and Catalan survival data. BMC Cancer. 2009;9:98.
Duffy, SW, Tabar, L, Chen, H-H, et al.
The impact of organized mammography service screening on breast carcinoma mortality in seven Swedish counties. Cancer. 2002;95:458–469.
Eaker, S, Dickman, PW, Bergkvist, L, Holmberg, L, Uppsala/Orebro Breast Cancer Group. Differences in management of older women influence breast cancer survival: Results from a population-based database in Sweden. PLoS Med. 2006;3:e25.
Eaker, S, Dickman, PW, Hellstrom, V, et al.
Regional differences in breast cancer survival despite common guidelines. Cancer Epidemiol Biomarkers Prev. 2005;14:2914–2918.
Eaker, S, Halmin, M, Bellocco, R, et al.
Social differences in breast cancer survival in relation to patient management within a National Health Care System (Sweden). Int J Cancer. 2009;124:180–187.
Halmin, M, Bellocco, R, Lagerlund, M, et al.
Long-term inequalities in breast cancer survival–a ten year follow-up study of patients managed within a National Health Care System (Sweden). Acta Oncol. 2008;47:216–224.
Hartman, M, Lindstrom, L, Dickman, PW, et al.
Is breast cancer prognosis inherited?
Breast Cancer Res. 2007;9:R39.
Hemminki, K, Ji, J, Forsti, A, Sundquist, J, Lenner, P. Survival in breast cancer is familial. Breast Cancer Res Treat. 2008;110:177–182.
Hussain, SK, Altieri, A, Sundquist, J, Hemminki, K. Influence of education level on breast cancer risk and survival in Sweden between 1990 and 2004. Int J Cancer. 2008;122:165–169.
Hussain, SK, Lenner, P, Sundquist, J, Hemminki, K. Influence of education level on cancer survival in Sweden. Ann Oncol. 2008;19:156–162.
Jonsson, H, Nystrom, L, Tornberg, S, Lenner, P. Service screening with mammography of women aged 50–69 years in sweden: Effects on mortality from breast cancer. J Med Screen. 2001;8:152–160.
42. Lagerlund, Bellocco, R, Karlsson, P, Tejler, G, Lambe, M. Socio-economic factors and breast cancer survival–A population-based cohort study (Sweden). Cancer Causes Control. 2005;16:419–430.
Lindstrom, LS, Hall, P, Hartman, M, et al.
Familial concordance in cancer survival: A Swedish population-based study. Lancet Oncol. 2007;8:1001–1006.
Manjer, J, Andersson, I, Berglund, G, et al.
Survival of women with breast cancer in relation to smoking. Eur J Cancer. 2000;166:852–858.
Nystrom, L, Andersson, I, Bjurstam, N, et al.
Long-term effects of mammography screening: Updated overview of the Swedish randomised trials. Lancet. 2002;359:909–919.
Rutqvist, LE., Bern, A, Stockholm Breast Cancer Study Group. Socioeconomic gradients in clinical stage at presentation and survival among breast cancer patients in the Stockholm area 1977–1997. Int J Cancer. 2006;119:1433–1439.
Tabar, L, Yen, M-F, Vitak, B, et al.
Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening. Lancet. 2003;361:1405–1410.
Warwick, J, Tabar, L, Vitak, B, Duffy, SW. Time-dependent effects on survival in breast carcinoma: Results of 20 years of follow-up from the Swedish Two-County Study. Cancer. 2004;100:1331–1336.
National Institute for Health and Clinical Excellence. Early and locally advanced breast cancer: Diagnosis and treatment (CG80). Updates and replaces technology appraisal guidance 109 (docetaxel), 108 (paclitaxel) and 107 (trastuzumab). London: National Institute for Health and Clinical Excellence; 2009.
National Institute for Health and Clinical Excellence. Advanced breast cancer: Diagnosis and treatment (CG81). Updates and replaces NICE technology appraisal guidance 62 (capecitabine), 54 (vinorelbine) and 30 (taxanes). London: National Institute for Health and Clinical Excellence; 2009.
National Institute for Health and Clinical Excellence. Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer (TA112). London: National Institute for Health and Clinical Excellence; 2006.
National Institute for Health and Clinical Excellence. Gemcitabine for the treatment of metastatic breast cancer (TA116). London: National Institute for Health and Clinical Excellence; 2007.
National Institute for Health and Clinical Excellence. Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer (TA214). London: National Institute for Health and Clinical Excellence; 2011.
Ministerio de Sanidad y Politica Social. Estrategia en Cancer del Sistema Nacional de Salud (Cancer Strategy). Spain: Ministerio de Sanidad y Politica Social; 2010.
Clinical Guideline Working Group on behalf of the Spanish Society of Medical Oncology (SEOM). SEOM clinical guidelines for the treatment of early breast cancer. Clin Transl Oncol. 2010;12:711–718.
Clinical Guideline Working Group on behalf of the Spanish Society of Medical Oncology (SEOM). SEOM clinical guidelines for the treatment of metastatic breast cancer. Clin Transl Oncol. 2010;12:719–723.
Engholm, G, Ferlay, J, Christensen, N, et al.
NORDCAN–a Nordic tool for cancer information, planning, quality control and research. Acta Oncol. 2010;49:725–736.
National Board of Health and Welfare (Socialstyrelsen). Cancer i Sverige, Insjuknande och överlevnad utifrån regional och socioekonomisk indelning. Stockholm: Socialstyrelsen; 2011.
National Board of Health and Welfare (Socialstyrelsen). Nationella riktlinjer för bröstcancersjukvård, Medicinskt och hälsoekonomiskt faktadokument. Stockholm: Socialstyrelsen; 2007.
Onkologiskt Centrum. Bröstcancervården i norra regionen.Regionala öppna jämförelser mellan landsting och sjukhus i norra sjukvårdsregionen. Umeå: Onkologiskt Centrum, 2009.
Styrgruppen för det Nationella Bröstcancerregistret. Bröstcancer, Nationell rapport diagnosår 2008. Stockholm: Onkologiskt Centrum; 2010.
Svenska BröstcancerGruppen (Swedish Breast Cancer Group). Nationella riktlinjer för behandling av bröstcancer. Stockholm: SweBCG; 2010.
Richards, M. An independent review is under way. BMJ. 2011;343:d6843.
Wilking, N, Kasteng, F. A review of breast cancer and outcomes in 18 countries in Europe, Asia, and Latin America. Comparator Report. Stockholm: Karolinska Institute; 2009.
Autier, P, Boniol, M, Gavin, A, Vatten, LJ. Breast cancer mortality in neighbouring European countries with different levels of screening but similar access to treatment: Trend analysis of WHO mortality database. BMJ. 2011;343:d4411.
Autier, P, Boniol, M. Caution needed for country-specific cancer survival. Lancet. 2011;377:99–101.
Bergkvist, L, Bixo, M, Björkelund, C, et al.
Hormone Replacement Therapy (HRT): An evidence based review. Report number: 159. Stockholm, Sweden: Swedish Council on Technology Assessment in Health Care; 2002.
Prentice, RL. Postmenopausal hormone therapy and the risks of coronary heart disease, breast cancer, and stroke. Semin Reprod Med. 2014;32:419–425.